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Clinical Observations 
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Abstracts: Traditional Chinese patent medicines (TCPMs) are widely used for treatment of chronic hepatitis B 
(CHB) in China. To estimate the overall effectiveness of TCPMs for CHB, we performed a systematic review of 
clinical reports designed as randomized controlled trials (RCTs). One hundred and thirty-eight available RCTs and 
quasi-RCTs on 62 TCPMs, involving 16,393 patients, were included. The methodological quality of these trials was 
generally “poor”. Few trials (6.52%) reported the methods of randomization correctly. Another common problem 
was the lack of allocation concealment, proper blinding, and the reporting of lost cases and dropouts. Forty-two 
trials (30.43%) on 27 TCPMs reported some anti-viral effect of TCPMs. Others reported beneficial aspects, 
including improvements of liver function (79.71% of the studies), liver fibrosis (29.99%), and CHB symptoms 
(92.75%). Forty-one articles (29.71%) reported mild adverse events with TCPMs but these occurred infrequently. In 
summary, the outcome of the report on currently registered TCPMs may be biased due to poor methodology. The 
data from these trials, therefore, is too weak to use in forming a recommendation for treatment of CHB. 
Nevertheless, five drugs (Dan Shen agents, Da Huang Zhe Chong pill/capsule, Shuang Hu Qing Gan granule, Fu 
Zheng Hua Yu granule and Cao Xian Yi Gan capsule) appear to be more effective than the other TCPMs.
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The hepatitis B virus (HBV) causes chronic infection in 
approximately 400 million people worldwide. It is 
estimated that 50% of male carriers and 14% of female 
carriers will eventually die of complications from 
cirrhosis and hepatocellular carcinoma.1 Interferon alpha 
agents, and nucleoside and nucleotide analogues are
widely used for treatment of chronic hepatitis B (CHB). 
Nevertheless, the incomplete anti-viral efficacy and the 
drug-resistant phenomena of these agents are still a 
challenge in clinical practice and are an active area of 
research. HBV infection has become one of the most 
serious public health problems in China. The use of 
traditional Chinese medicine (TCM) is an appreciable 
distinction in the treatment of CHB between China and 
the western world. Traditional Chinese patent medicines 
(TCPMs) are developed by combining modernized 
pharmaceutical technologies with ancient TCM theories. 
Refined dosage forms and relative standardization in 
composing the main effective substances are considered 
real advantages of TCPMs compared with the traditional 
Chinese decoction. This combination provides the 
convenience of administration and allows for efficacy 
evaluation in clinical trials. 
TCM has a long history in treating many diseases, 
including CHB. Although this ancient medicine is 
commonly thought of as complementary or alternative in 
the western world, it is still widely accepted in China by 
patients and practitioners, and used in both TCM and 
western medicine hospitals. Several systematic reviews 
have been published in English to evaluate TCM or 
Chinese herbs for CHB.2-4 However, few systematic 
reviews of TCPMs for CHB have been made, although 
they already make up a considerable proportion of the 
medical cost for Chinese CHB patients. Moreover, the 
use of TCPMs is vaguely recommended in the guidelines 
for treatment of CHB issued by the Chinese Medical 
Association.5 There is still uncertainty regarding the 
clinical efficacy of TCPMs for the treatment of CHB. In 
addition, there is confusion regarding the selection of 
TCPMs for patients with CHB since there is no reliable 
way to select the best medicine from the large pool 
available from so many available. Based on the 
challenges that exist in clinical practice, we sought to 
quantitatively assess the quality, and overall efficacy of 
TCPMs for CHB treatment, and to determine which  of 
them have stronger evidence-based data. 
METHODS
Study Identification 
This review was restricted to the TCPMs listed in the 
2009 State Food and Drug Administration (SFDA) 
website (http://www.sda.gov.cn). We first searched for 
studies using any form of TCM therapy for CHB before 
screening for interventions that included drugs in the 
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database of registered TCPMs at SFDA. In addition, we 
conducted searches using the drug names as key words to 
find potential missing trials for each drug.  
Five reviewers (Zhang Tao, Wei Xing, Chen Ze-qi, Wang 
Dong-sheng, and Dai Xing-ping) independently searched 
the MEDLINE database (1966 to December 2009), 
EMBASE (1980 to December 2009), and CBM-disc 
(China Biological Medicine Database, 1979 to December 
2009). We used a very sensitive strategy to identify all 
possible studies. The searching terms were: a) traditional 
Chinese medicine (TCM); b) Chinese herbs; and c) 
chronic hepatitis B. We searched the SFDA website using 
all drug names acquired from retrieved studies to 
determine whether the drugs were in the list of TCPMs 
registered by SFDA. We also identified additional studies 
by searching the reference lists of all the relevant articles 
using Google and then contacting the manufacturers. The 
latter measure was to acquire information on additional 
published and unpublished studies.  
Study Selection
We selected the alleged randomized controlled trials 
(RCTs) for all of the TCPMs for CHB listed on the 
SFDA website. The trials were double blinded, single 
blinded or non-blinded. 
Trials that enrolled patients of any age, sex or ethnic 
origin with CHB were eligible. The diagnosis of CHB 
was defined as serum HBsAg positive persisting six 
months or more, accompanied by elevated alanine 
aminotransferase (ALT) and/or aspartate amin- 
otransferase (AST) or with recurrent fluctuation, whether 
symptomatic or symptomless, and with or without liver 
biopsy findings compatible with chronic hepatitis.5 Trials 
of subjects with super-infection or co-infection of CHB 
with another hepatitis virus were excluded. 
The mode of intervention could be a single TCPM 
compared with placebo or no intervention, or regular 
non-specific treatments such as vitamins, or interferon-α
(IFN-α) treatment (no limitation regarding IFN type or 
IFN treatment regimen), or nucleoside and nucleotide 
analogues. Combinations of a TCPM with another 
treatment compared with the same treatment were also 
included. 
The trials that met the above criteria were included 
regardless of treatment duration or dosage. The primary 
outcome measures were evaluated, including: 1) 
mortality; 2) occurrence of hepatocellular carcinoma or 
liver cirrhosis; 3) loss of serum HBeAg; 4) 
seroconversion of HBeAg to HBeAb (antibody against 
HBeAg); 5) loss of serum HBV DNA; 6) loss of serum 
HBsAg; 7) normalization or decrease of ALT and/or AST 
levels; 8) liver histological recovery; 9) serum markers 
of liver fibrosis including hyaluronic acid (HA), type IV 
collagen (IVC),type III procollagen (PIIIP), and laminin 
(LN); 10) quality of life; and 11) adverse events. 
Quality Assessment and Data Analysis 
Three reviewers (Zhang Tao, Wei Xing, and Dai 
Xing-ping) independently selected trials that met the 
inclusion criteria and extracted the study details, which 
included randomization, allocation concealment, 
blinding, intention-to-treat analysis, case dropouts lost to 
follow-up, patient data, methods, interventions, and 
outcomes. Authors were contacted, if needed, to obtain 
information beyond that contained in the published 
papers. 
The extracted data within a comparison was estimated if 
there were RCTs with similar quality available. If 
possible, we performed data analysis in conjunction with 
the Review Manager 5 (The Cochrane Library). 
RESULTS
General Study Characteristics 
Using our search strategy, we found 62 TCPMs
registered by SFDA, with 138 available RCTs or 
quasi-RCTs, all of which were published in Chinese 
language journals and conducted in China from 1991 to 
2009 (see Table 1 and Figure 1). The age of patients 
ranged from 2 to 84 years. More males were included in 
each study than females. The sex proportion of the 
subjects varied remarkably (3.89:1 to 1.93:1). 
Figure 1. Flow chart of inclusion and exclusion criteria, 
and study selection. 
One hundred and thirty-two trials (95.65%) applied the 
national diagnostic criteria for CHB in different time 
periods (from 1980 to 2005), but were essentially the 
3212 papers were obtained from 
the research of all clinical studies 
on TCM for CHB. 
153 of the remaining 376 studies 
on TCPMs for CHB mentioned 
randomization of allocation. 
2836 papers were excluded because 
the studied drugs could not be found in 
the list of TCPMs on website of SFDA.
138 studies on 62 TCPMs were 
included for further appraisal. 
15 articles were excluded because 
they were previously published or 
had repeated data. 
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same. The remaining 6 studies had no clear diagnostic 
criteria. The duration of HBV infection before treatment 
varied from 6 months to over 30 years. The total duration 
of treatment with TCPMs varied from 3 weeks to 1 year. 
The dosage forms of the included TCPMs were pill, 
tablet, injection, granule and liquid. The intervention 
modalities were a TCPM compared with other agents, 
and a TCPM plus an anti-viral agent or non-specific 
treatment compared to the same treatment in a control 
group. 
Table 1. The Included RCTs or Quasi-RCTs on 62 TCPMs, and subjects. 
TCPMs RCTs or 
quasi-RCTs 
Patients TCPMs RCTs or 
quasi-RCTs 
Patients 
Dan Shen agents 15 1408** Gan De Zhi (tablet) 1 300 
Da Huang Zhe Chong 
pill/capsule 
9 817** Gan Long capsule 1 28 
Shuang Hu Qing Gan granule 7 1106** Gan Luo Xin capsule 1 123 
An Luo Hua Xian pill 6 556* Tan Re Qing injection 1 60 
Ye Xia Zhu capsule 6 496 Xiao Zhen Yi Gan tablet 1 60 
Huang Qi injection 5 546* Yu Jin injection 1 38 
Fu Zheng Hua Yu capsule 5 494 Fu Fang Mu Ji granule 1 126 
Fu Fang Bie Jia Ruan Gan 
tablet 
4 346 Chui Pen Cao granule 1 300 
Cao Xian Yi Gan capsule 4 958** Da Huang injecting 1 290 
Hu Ju Yi Gan capsule 4 662* Gan Fu Le (tablet) 1 58 
Wu Ling Dan pill 4 509* Li Gan tablet 1 45 
Dang Fei Li Gan Ning capsule 3 283 Li Gan Long (tablet) 1 83 
Liu Wei Wu Ling pill 3 658* Ling Zhi capsule 1 60 
Qiang Gan capsule 3 208 Huang Xuan Yi Gan granule 1 124 
Fu Gan Kang granule 3 558* Bie Jia Jian pill 1 164 
Fu Fang Ku Shen injection 3 212 Fu Fang San Ye Xiang Cha Cai 
tablet 
1 98 
Gan Fu Kang tablet 2 550* Xiao Yao pill 1 37 
Gan Su granule 2 286 Wu Zhi capsule 1 84 
Gan Shu capsule 2 135 Tui Hung Li Dan liquid 1 80 
Qing Gan Li Dan liquid 2 159 Zhen Qi Fu Zheng capsule 1 60 
Qing Kai Ling injection 2 462 Wu Ling Dan capsule 1 94 
Xiao Chai Hu pill/granule 2 221 Bai Ling capsule 1 60 
Yin Zhi Huang injection 2 135 Xue Sai Tong injection 1 102 
Chao Yang pill 2 385 Fructus Lycii glucopeptide 
capsule 
1 60 
He Luo Shu Gan capsule 1 176 Deng Zhan Hua injection 1 50 
Shu Gan Ning injection 1 80 Deng Zhan Xi Xin injection 1 100 
Hu Gan Ning tablet 1 148 Yi Gan Ning granule 1 138 
Jia Qi Gan Xian granule 1 407 Lentinan tablet 1 82 
Ke Huang granule 1 82 Mei Hua Dian She pill 1 47 
Gan Du Jing (granule) 1 104 Mai Luo Ning injection 1 125 
Gan Yan Ling injection 1 90 Ao Tai Le granule 1 180
Notes: *Subjects>500 in total; ** Subjects>800 in total. 
Study Quality Assessment
All of the included studies claimed randomization in the 
description of methods and case allocation. However, 
only nine studies6-14 reported the correct methods of 
randomization (random numbers generated by computer 
or using random number table); but one trial10 on the Fu 
Zheng Hua Yu capsule had a grade “A” level of adequate 
concealment of allocation because it allocated cases via 
random numbers generated by a statistics center which 
was independent from those conducting the trial. Six 
trials8,10,15-18 mentioned the use of single or double 
blinding, but 5 of them8,15-18 were missing the subject 
description. Only one trial10 on the Fu Zheng Hua Yu 
capsule reported the participants lost to follow-up and 
used intention to treat analysis. The remaining 137 
studies all neglected reporting patients lost and dropouts 
(Table 2). Interestingly, 116 studies conducted baseline 
data comparison between each pair of the experimental 
and control groups. All 116 studies reported good 
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baseline consistency despite the minority of studies with randomization methods.  
Table 2. Studies of TCPMs with Jadad Score >1 
Intervention Study 
Experimental Control 
Description for 
Randomization 
Description for 
Blinding 
Allocation 
concealment 
Case Lost or 
Dropouts 
Patients Jadad 
score 
Jin, et 
al.6  
DS SM Randomized, 
Clear 
Non-blinded Unclear Unreported 79 2 
Yu7 SHQG+LAM LAM Randomized, 
Clear 
Non-blinded Unclear Unreported 120 2 
Shu9 SHQG+LAM LAM Randomized, 
Clear 
Non-blinded Unclear Unreported 121 2 
Qiu, et 
al16 
SHQG + Vit. Vit. Randomized, 
Unclear 
Single-blinded, 
Unclear 
Unclear Unreported 135 1̚2♦
Hou, et 
al8 
SHQG YGQRJD Randomized, 
Clear 
Single-blinded, 
Unclear 
Unclear Unreported 206 2̚3♦
Zhang, 
et al15 
SHQG YGQRJD Randomized, 
Unclear 
Single-blinded, 
Unclear 
Unclear Unreported 206 1̚2♦
Liu, et 
al10 
FZHY HLSG Randomized, 
Clear 
Double-blinded, 
Clear 
Clear Reported 216 5 
Liang11 FFKS TMP Randomized, 
Clear 
Non-blinded Unclear Unreported 64 2 
Xiao12 SGN PMA Randomized, 
Clear 
Non-blinded Unclear Unreported 80 2 
Qi, et 
al13 
WLD GSK Randomized, 
Clear 
Non-blinded Unclear Unreported 94 2 
Yang, et 
al14 
ATL ZLGPK Randomized, 
Clear 
Non-blinded Unclear Unreported 180 2 
Cheng, 
et al17 
GS BFD Randomized, 
Unclear 
Double-blinded, 
Unclear 
Unclear Unreported 72 2 
Zhang, 
et al18 
YGN ONA Randomized, 
Unclear 
Double-blinded, 
Unclear 
Unclear Unreported 138 2 
Notes: DS: Dan Shen injection; SM: Shen Mai injection; SHQG: Shuang Hu Qing Gan granule; LAM: Lamivudine tablet; Vit.:vitamins; 
YGQRJD: Yi Gan Qing Re Jie Du granule; FZHY: Fu Zheng Hua Yu capsule; HLSG: He Luo Shu Gan capsule; FFKS: Fu Fang Ku Shen 
injection; TMP: Thymopetidum injection; SGN: Shu Gan Ning injection; PMA: Potassium Magmesium Aspartate injection; WLD: Wu Ling 
Dan pill; GSK: Gan Su Kang capsule; ATL: Ao Tai Le granule; ZLGPK: Zhong Long Gan Pi Kang capsule; GS: Gan Shu capsule; BFD: 
Bifendate tablet; YGN: Yi Gan Ning granule; ONA: Oleanolic Acid.♦Studies were scored between 1 and 2, or 2 and 3 because the trials were 
single-blinding, not double-blinding as demanded by principle of strict RCT design. 
Anti-viral Effects 
Seventy-two (52.17%) of the included trials on 38 
TCPMs observed the anti-viral effect for CHB. Of these 
forty-two (30.43%) on 27 TCPMs concluded that the 
TCPMs had some anti-viral effect. Twenty trials 
estimated the anti-viral effect of TCPMs plus a 
conventional anti-viral agent (Lamivudine, Adefovir, 
Dipivoxil, Entecavir, or IFN agents) compared with the 
same conventional anti-viral agent applied alone as 
control. The remaining 52 trials used TCPMs or TCPMs 
plus a non-specific treatment compared with a 
non-specific treatment as the control. Here, A 
non-specific treatment refers to regimens that were not 
considered to have any anti-viral activity, which in these 
reports included: 1) Diammonium Glycyrrihizinate; 2) 
Tiopronin; 3) Hepatocyte Growth-Promoting Factors; 4) 
Potassium Magnesium Aspartate; 6) Vidarabine; 7) 
Oleanolic Acid; 8) Silibin Meglumine; 9) Bifendate; 10) 
Thymopetidum; 11) Heparin Sodium; 12) Vitamins; 13) 
other TCPMs and Chinese herbal medicines.  
Liver Function Protection 
One hundred and twelve trials (81.16%) indicated that 
TCPMs protect liver function in terms of normalization 
or decrease of ALT or ALT/AST. One hundred and ten 
trials (79.71%) reported that TCPMs lowered the 
aminotransferase level, regardless of variation due to 
different dosage and duration of follow-up. The drugs 
used in the control groups largely varied among trials in 
each single TCPMs. Furthermore, 73 trials (52.90%) 
reported the detailed value change of ALT and/or AST 
while the other trials (28.26%) merely reported the 
normalization rate of ALT and/or AST level, or just 
stated ALT and/or AST level, without providing the 
actual value. This is one of the parameters that was 
estimated to reflect the overall efficiency of the TCPMs.  
Twelve trials (8.70%) on 6 TCPMs reported liver 
histological recovery by liver biopsy. All 12 trials 
claimed that TCPMs improved liver histology. Five trials 
(3.62%) on 3 TCPMs used the Knodell histologic 
activity index (HAI) to reflect inflammatory activity, 
while the remaining 7 trials only mentioned having 
conducted a liver biopsy but did not provide detailed 
grades. 
Anti-fibrosis Effect 
Forty trials (29.99%) on 20 TCPMs reported an 
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anti-fibrosis effect of TCPMs. Only 1 trial (0.72%)10 on 
the Fu Zheng Hua Yu capsule conducted liver biopsies to 
assess the fibrosis grades. The remaining 39 trials
(28.26%) used serum markers (HA,IVC, PIIIP, LN) to 
estimate liver fibrosis. Different agents were applied 
either together with the TCPMs or as a control drug 
within the same study, which had more than one study 
included. 
Quality of Life 
None of the trials systematically evaluated quality of life. 
However, 128 trials (92.75%) reported the therapeutic 
effect of TCPMs in improving the symptoms of CHB, 
although no common evaluation criteria or scale was 
applied. The primary symptoms that could be improved 
by TCPMs were: 1) jaundice; 2) abdominal distension; 3) 
poor appetite; 4) hypodynamia; 5) splenomegalia; and 6) 
hepatomegalia. 
Forty-one trials (29.71%) showed that mild adverse 
events occurred when treating with TCPMs. These trials 
suggested that TCPMs demonstrated good safety since 
no severe adverse events were verified during the trials 
or during follow-up. The remaining 97 trials (70.29%) 
did not state the occurrence of adverse events. Thirty-two 
trials (23.19%) conducted conventional tests such as 
routine blood, urine, stool, renal function, and heart tests 
(electrocardiogram). No obvious changes were reported 
relating to these tests. The reported adverse events were: 
1) allergic reactions; 2) nausea; 3) constipation; 4) 
diarrhea; 5) dizziness; and 6) mild blood pressure change. 
All adverse effects disappeared without special treatment. 
Five drugs had one or more studies reporting a higher 
incidence of adverse events in the experimental group 
than the control group (Table 3).  
Table 3. TCPMs with at Least One Study Reporting Higher Incidence of Adverse Events than the Control Agents 
Experimental Control TCPMs studies
Events(cases) Total(subjects) Events(cases) Total(subjects)
Adverse Reactions 
from TCPMs 
An Luo Hua Xian Pill 1 12 121 4 59 C, D 
Dan Shen agents 2 11 114 15 169 A, E 
Fu Zheng Hua Yu capsule 1 9 164 5 112 C, D 
Shuang Hu Qing Gan granule 1 4 167 2 154 B, C 
Wu Ling pill 2 3 192 0 101 A, C, D 
Notes: A: allergic reactions; B: nausea; C: constipation; D: diarrhea; E: dizziness. 
Hepatocarcinoma, Liver Cirrhosis, and Mortality 
No trial reported events of hepatocellular carcinoma, 
liver cirrhosis, or mortality. 
Individual Drug Analysis 
The TCPMs that are relatively promising for future 
research and clinical practice for CHB, were generally 
studies having more participants (>800 in total) or a little 
higher quality (Jadad score>2). These studies were 
analyzed to provide a more quantitative assessment.  
Dan Shen Agents 
Dan Shen (Salvia Miltiorrhiza) is a very popular Chinese 
herb prescribed mainly for vascular diseases, such as 
coronary disease and cerebral infarction. However, we 
found that Dan Shen agents had most of the RCTs for 
CHB among our selected TCPMs. Dan Shen was 
originally used for treatment of the syndrome “stagnation 
or heat of blood”, manifested in a variety of diseases. 
Some experimental studies have demonstrated the 
pharmacological effects of Dan Sheng herb or its extracts 
on liver impairment.19-23 The dosage forms used for Dan 
Sheng agents were injection (10 studies), pills (4 studies), 
and liquid (1 study). Seven trials, all with duration of 
treatment longer than 6 months, evaluated whether or not 
Dan Shen agents had an anti-viral effect. Three reported 
that Dan Shen agents improved HBV serum markers or 
HBV DNA levels, while the other four trials claimed no 
significant difference compared to controls. Twelve of 
the 15 studies reported that Dan Shen agents may 
significantly improve ALT and/or AST levels. Five 
studies reported that Dan Shen agents improved hepatic 
fibrosis, as monitored by serum markers. Fourteen 
studies stated that Dan Shen may help recovery from 
symptoms induced by CHB. Only one study6, with Shen 
Mai injection as the control drug, reported that Dan Shen 
group had less improvement of the symptoms of hepatitis 
as well as serum aminotransferase levels. This study had 
a Jadad score of 2, whereas the rest all scored 14, which 
means it is the only definitive randomized trial on Dan 
Shen agents. Comparison of Dan Shen with Sheng Mai 
injection with respect to improvement of symptoms, 
yielded an odds ratio (OR) of 0.25 with a 95% 
confidence interval (95% CI) of 0.08 to 0.84. Using data 
from this single RCT, the standard mean difference 
(SMD) and its 95% CI when comparing ALT and AST 
changes were 2.03 [CI: 1.48, 2.59] and 1.13 [0.65, 1.62], 
respectively. In contrast, the RCT using Dan Shen 
injection reported favorable improvements in hepatic 
fibrosis serum markers, HA, IVC, PIIIP and LN. The 
SMD and 95% CI were -0.65 [-1.11, -0.19], -0.90 [-1.37, 
-0.43], -0.52 [-0.98, -0.06] and -0.71 [-1.18, -0.25] 
respectively. Because of the divergence of study quality, 
selection of controls, and drug combination, meaningful 
data synthesis could not be made from the 15 reports. 
Da Huang Zhe Chong Pill/Capsule 
The Da Huang Zhe Chong pill is a very famous Chinese 
herb formula that originated in the classic “Jinguiyaolue” 
by Zhang Zhongjing in the East Han dynasty. We 
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identified two dosage forms with identical composition 
of Chinese herbs. Unfortunately, no quality RCT was 
found in the database on this historical drug for the 
treatment of CHB. However, it already had nine possible 
RCTs (Jadad score <2) without any description of a 
randomization method and had a large number of 
subjects. No trial reported that the Da Huang Zhe Chong 
pill/capsule had anti-viral effects, by 
mono-administration and did not enhance the anti-viral 
effects of other conventional agents. Six trials stated that 
a Da Huang Zhe Chong pill/capsule had better efficacy 
in treating elevated serum ALT and/or AST levels, 
especially for hepatitis symptoms, and that non-specific 
control drugs or mono-therapy of conventional IFN-α. 
Five trials (413 subjects) testing Da Huang Zhe Chong 
pill/capsule plus non-specific drugs as the experimental 
intervention, reported that ALT levels significantly 
decreased after treatment in the experimental groups 
relative to control groups using the same non-specific 
drugs. The pooled SMD had a 95% CI of -2.23 [-4.21, 
-1.06] with a heterogeneity test: P=0.31, and I2=21%. 
The most interesting finding from CHB Da Huang Zhe 
Chong pill/capsule trials may be its anti-fibrosis effects. 
That is, seven studies (633 participants) reported that 
compared with non-specific treatments, combining Da 
Huang Zhe Chong pill/capsules with non-specific agents 
significantly lowered serum marker levels of hepatic 
fibrosis. The pooled SMD and 95% CI of HA, IVC, PIIIP 
and LN were -0.98 [-1.31, -0.12], -1.21 [-3.01, -0.66], 
-1.54 [-3.21, -1.01] and -2.03 [-3.47,-0.96] respectively. 
Sensitivity tests were not justified due to the 
heterogeneity among the trials, so it was not significant 
for each serum marker (P>0.05, I2<50%).  
Shuang Hu Qing Gan granule 
The effectiveness of Shuang Hu Qing Gan granules was 
outstanding in the 62 TCPMs assessed as there were 5 
studies with a Jadad score >1. Two trials (241subjects),7,9
with a Jadad score of 2, used an intervention mode of 
Shuang Hu Qing Gan granules together with Lamivudine, 
versus Lamivudine mono-therapy. Both studies reported 
that the combination of Shuang Hu Qing Gan granules
with Lamivudine did not show better results in HBV 
serum markers and HBV DNA levels after a 1-year of 
treatment and another 1 year of follow-up, than that seen 
for Lamivudine mono-therapy. Interestingly, Shu’s study 
9 stated that this combination lowered the occurrence of 
YMDD HBV mutations after 1-year of treatment. The 
OR and 95% CI were 0.37 [0.15, 0.88] between the 
experimental and control groups. Another two studies 
(412 subjects), 8,15 with a Jadad score of 2–3, and 1–2, 
used Yi Gan Qing Re Jie Du granules, which is an 
unidentified TCPM in this review, and served as the 
control drug. The two studies reported that Shuang Hu 
Qing Gan granules had anti-viral effects, and improved 
the serum aminotransferase levels and hepatitis 
symptoms. The pooled OR and 95% CI of HBeAg 
negative seroconversion were 3.83 [1.08, 13.61] with a 
significant heterogeneity between the two studies 
(P=0.02, I2 =82%). The pooled SMD and 95% CI were 
-0.36 [-1.06, 0.34] with significant heterogeneity 
(P=0.009, I2=91%) in ALT changes, and -0.37 [-0.96, 
0.22] with significant heterogeneity (P=0.006, I2 =87%) 
in AST changes. The pooled OR and 95% CI of 
improved symptoms were 2.92 [0.62, 13.75], with 
significant heterogeneity (P=0.006, I2=87%). The 
remarkable heterogeneity might result from a divergence 
in study quality.
Fu Zheng Hua Yu capsule 
The trail with Fu Zheng Hua Yu capsule was the only 
high-quality study10 with a Jadad score of 5. The study 
was conducted exactly in accordance with the 
Consolidated Standards of Reporting Trials (CONSORT), 
Nine clinical centers and 216 subjects were involved in 
this single RCT. The study, with a 24-week treatment and 
a 12-week follow-up, did not exhibit the anti-viral effect 
of Fu Zheng Hua Yu capsule, whereas it did report 
improvement in liver function and hepatic fibrosis. The 
most valuable result of the trial was that this TCPM 
significantly improved liver impairment, as reflected by 
93 liver biopsy samples⎯the gold standard of 
inflammatory fibrosis diagnosis. Biopsy samples treated 
with Fu Zheng Hua Yu capsule showed significantly 
lower grades on both liver inflammation (G) and fibrosis 
(S), than the control TCPM. The control He Luo Shu 
Gan capsule did not improve liver histology after the 
same duration of treatment, even though it is also a 
registered TCPMs identified in our systematic review. 
The OR and 95% CI of effective power on hepatic 
fibrosis were 3.58 [1.45, 8.79], which was consistent 
with the comparison of fibrosis serum markers with OR 
and 95% CI on effective power estimated 7.09 [3.89, 
12.90]. The study also reported that Fu Zheng Hua Yu 
capsule had significantly better effective power on the 
ALT normalization than the control group, and the OR 
and 95% CI were 1.82 [1.03, 3.22]. No adverse event 
was found in the experimental group, whereas one case 
of a mild adverse event occurred in the control group. 
These results suggest a good safety profile of Fu Zheng 
Hua Yu capsule. The other four, low-quality studies, all 
with a Jadad score of 1, had similar positive results 
except for the anti-HBV effect. 
Cao Xian Yi Gan capsule 
Cao Xian Yi Gan capsule had 4 RCTs for CHB 
encompassing 958 subjects. Unfortunately, no study had 
a Jadad score >1. Three of them (780 participants) 
reported that this TCPM showed anti-HBV effect for a 6- 
or 12-month treatment. All 4 studies reported Cao Xian 
Yi Gan capsule had significant benefits, including 
elevation of ALT, and improving symptoms of hepatitis. 
Three of the studies (774 participants) used Fu Gan Ning 
tablet, and an unidentified TCPM identified in our 
systematic review, as the control mono-therapy. The 
pooled SMD of the 3 trials on ALT changes after a 4 
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week of treatment were -0.40 [-0.76, 0.09], with 
marginal significant heterogeneity (P=0.08, I2=46%). 
The pooled OR and 95% CI of effective power on 
symptoms were 2.01 [1.27, 3.20], with marginal 
significant heterogeneity (P=0.14, I2 =49%). 
DISCUSSION
Infectious hepatitis B is a serious health problem in 
China. Among global deaths attributed to hepatitis B, 
approximately 40% occur in China.24 CHB has become 
one of the hot topics of basic research and clinical 
practice of TCM.25 Although various anti-viral agents 
have been used in China, doctors still tend to prescribe 
different kinds of TCPMs, considering the incomplete 
HBV clearance, drug resistance. and the high cost of 
western medicine.  
This is the first comprehensive systematic review of 
government-approved TCPMs for CHB. Here, we restrict 
the category of TCPMs within a range of drugs for which 
the composition and use are based on the unique theory 
of TCM. This kind of theory may sound vague and 
irrational for most western medicine doctors. It is 
necessary to elucidate the mechanisms of TCM in terms 
of modern science and to standardize the dosage and 
clinical use of TCM. In fact, the integration of traditional 
Chinese medicine with western medicine has long been a 
state health policy in China. TCPMs play an important 
role in the policy, since under the guidance of traditional 
theories; TCPMs have a relatively stable quality control 
on the effective components via a series of 
pharmaceutical technologies and manufacturing 
management.26, 27  
The methods of TCM treatment are based on the 
principle of the so-called “syndrome differentiation” 
(Bian zheng). The syndrome in TCM theory is closely
related to the symptoms that the body presents, and 
refers to a natural philosophical determination on the 
overall status of the body. Different diseases sometimes 
have a common same syndrome in TCM. In China, 
TCPM prescriptions are made in accordance with the 
tradition of “syndrome differentiation”, which allows 
that the same TCPM can be used in treating various 
diseases. Considering the particular use of TCPMs, we 
first searched all studies evaluating any form of drugs in 
TCM and identified those with an experimental TCPM 
that was listed on the SFDA website. This approach was 
taken, rather than picking out names of some commonly 
used TCPMs as the firm search terms attempted to 
acquire sufficient studies for this review. The latter 
strategy actually may not be as sensitive as the former 
because some TCPMs that are usually prescribed for 
treatment of other diseases, may already have clinical 
trials that evaluated their efficacy for CHB. 
For most clinical interventions, a prospective RCT is the 
best way to evaluate efficacy and safety.28 We selected 
the alleged RCTs of TCPMs because they represent the 
best data when comparing with non-randomized trials. 
Assessment of methodology quality is the core mission 
of our systematic review, and the pivotal determination 
of whether or not the trials are reliable.29-31 However, we 
found very limited evidence from the RCTs regarding the 
effectiveness of TCPMs. Only one trial on Fu Zheng Hua 
Yu capsule was viewed as a reliable RCT, which may 
support the finding that Fu Zheng Hua Yu capsule has a 
beneficial effect on hepatic fibrosis and inflammation. 
The majority of the RCTs identified were designed 
poorly according to the Jadad scoring method and 
appraisal on allocation concealment. For those reports 
that lack randomization and allocation concealment 
details, whether the randomization was conducted 
effectively is doubtful, since inappropriate randomization 
and allocation can lead to selection bias. Performance 
bias may also exist because most of the RCTs assessed 
were single-center and non-blinded. In addition, the lack 
of reporting case dropouts and those lost in the trials 
might result in attrition bias, which increases the 
overestimation risk for TCPMs. Therefore, the results 
obtained from these poor-quality trials are far from 
convincing and the TCPMs need to be further evaluated 
well-designed trials. 
A large scale survey recently pointed out that among the 
authors who published clinical studies in Chinese 
language journals, there was a common lack of clear 
understanding of the methodological principles and a 
disregard for the scientific and social responsibility to 
use proper trial design.32 Our review may actually 
support the conclusion of the survey. More particularly, 
we restricted the scope to government-approved TCPMs 
and anticipated that the average quality of those trials 
would be better. Unfortunately, the result of our quality 
assessment was still disappointing. There are two 
possible explanations accounting for the official 
admittance of TCPMs by SFDA, despite the fact that 
only a minority was properly designed regarding CHB. 
First, most TCPMs included may have good-quality 
studies for diseases other than CHB, given the fact that 
the use of TCPM is based mostly on “syndrome 
differentiation” and application to various diseases. 
Second, the approval of a TCPMs by SFDA is not strictly 
based on clinical trial data, but also on the history of the 
applicant, in addition to the low incidence of severe 
adverse events.  
It is now clear that active HBV replication is the key 
driver of liver cirrhosis and hepatocellular carcinoma. 
Some TCPMs were reported to have some anti-viral 
effect. We sought to conduct a meta-analysis on two 
modalities: TCPMs versus non-specific treatment, and 
TCPMs plus TCPMs versus a conventional anti-viral 
agent. A “non-specific treatment” could be various drugs 
alone or in combination. We assumed that the anti-viral 
effect of TCPMs could independently appear when it was 
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not applied together with any anti-viral agents. 
Nevertheless, it was meaningless to perform meta- 
analysis on overall anti-viral effect because of the 
inadequate quality of the studies included. Moreover, we 
found an obvious divergence on the selection of control 
drugs and the intervention mode of the same drug, which 
led to the lack of eligible data for data synthesis, even if 
there had been no problem with the quality of source 
studies. 
Most of the trials included reported that TCPMs could 
protect the liver from inflammatory damage as it lowered 
the level of serum ALT and/or AST. Only 12 trials 
conducted liver biopsies, which is considered the “gold 
standard” for assessing liver damage. Another interesting 
finding was the reported therapeutic effect of TCPMs on 
liver fibrosis as determined by serum marker (HA, IVC, 
PIIIP, LN). Current research supports that idea that 
hepatic fibrogenesis is a common result of injury to the 
liver. It is believed to be a key factor that leads to hepatic 
dysfunction and may also be important in portal 
hypertension.33 This anti-fibrosis effect may be a 
potential benefit of TCPMs.  
Five drugs (Dan Shen agents, Da Huang Zhe Chong 
pill/capsule, Shuang Hu Qing Gan granule, Fu Zheng 
Hua Yu granule and Cao Xian Yi Gan capsule) were 
selected for individual analysis as they either had been 
studied with large sample sizes or with relatively better 
quality. These TCPMs have stronger current data in the 
literature relative to others. Data synthesis was 
conducted in spite of the low quality trial design so as to 
provide a more quantitative understanding for the 
validity of these drugs, rather than to provide any 
guidance for selection of TCPMs in clinical practice. 
Nevertheless, Fu Zheng Hua Yu granule should still have 
privilege of first consideration by doctors because it has 
a moderate scale, multi-center, prospective and 
well-designed RCT documenting efficacy and safety. 
Few adverse events have been reported in the included 
studies, which suggests that TCPMs are safe and 
nontoxic. However, this conclusion is still preliminary 
because there are no studies with sufficient long-term 
follow-up or sensitive toxicity tests. Several studies on 
the toxic and harmful profile of TCM have been 
published,34-36 which should remind us of being aware of 
the possible long-term and underlying TCPMs -induced 
adverse events. 
In conclusion, a definitive determination of TCPMs 
validity cannot be made from our appraisal because of 
the unclear methodological quality of the trials identified. 
The data is too weak to recommend a TCPM as the 
standard treatment for CHB. We need more well 
designed clinical trials to evaluate the efficacy and safety 
of TCPMs. Therefore, improving the methodological 
quality of relevant clinical trials should be a high 
priority.  
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